Disease Control and Prevention Vaccine Market - by Product Type (Live-Attenuated, Inactivated, Recombinant Sub Unit and Toxoid), by Type (Monovalent and Multivalent), By Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), and By Indication (Infectious Disease, Cancer and Other Indications) - Global Forecast to 2025

Published In : Apr 2018

Code : CMI1500

Pages :210

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Increasing Governmental Initiatives for Immunization Programs is Driving Growth of the Disease Control and Prevention Vaccine Market

Governmental and non-governmental organization partners are working together to provide better immunization to the population for complete disease eradication. For instance, the Global Polio Eradication Initiative was a public-private partnership between five governmental agencies - the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children’s Fund (UNICEF), and the Bill & Melinda Gates Foundation, aiming at polio eradication worldwide. The program was funded US$ 15 billion in the period 1988 - 2017, provided by public and private donors and 2013 - 2019 requirement was projected to US$ 7 billion. Furthermore, organizations such as Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the development of advanced influenza vaccines. Such governmental approaches are expected to augment the growth of the global disease control and prevention vaccine market over the forecast period (2017-2025). However, the high cost of vaccine development is expected to restrain the growth of the disease control and prevention vaccine market.